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8 ABSTRACT: A crystal growth technique, interfacial cocrystalli-
9 zation, is demonstrated to be a simple and effective method for
10 preparing multicomponent crystal forms. The technique is based
11 on the generation of a liquid−liquid interface between two
12 immiscible solutions of cocrystal-forming compounds, and its
13 utility is demonstrated through the preparation of polymorphs
14 and hydrates of caffeine cocrystals, involving three different
15 hydroxy-2-naphthoic acids, including the formation of some with
16 unexpected compositions.
17 ■ INTRODUCTION
18 Multicomponent crystals are widely utilized for crystal
19 engineering purposes in a variety of settings, including the
20 pharmaceutical industry.1 Cocrystals, which consist of at least
21 two different types of neutral molecules (coformers) held
22 together by noncovalent interactions (such as hydrogen
23 bonds), play an increasingly important role in drug develop-
24 ment owing to their capacity to enhance relevant chemical and
25 physical properties of drug molecules in the solid state2 (e.g.,
26 chemical stability,3 hygroscopicity,4 tabletability,5 or taste6).
27 The mounting number of patents and new FDA-approved
28 medicines7 based on pharmaceutical cocrystals also attest to
29 their potential and usefulness. Cocrystals are, however, prone to
30 polymorphism like all other types of molecular crystals,8,9 and
31 as a result it is essential to screen thoroughly for polymorphic
32 forms of cocrystals during product development.10
33 To date, various techniques have been developed for the
34 preparation of cocrystals on a laboratory scale,11−16 with the
35 majority being solvent based (e.g., solvent evaporation and
36 solvent cooling17,18). Solvent-based methods avoid partial
37 degradation of drug molecules during cocrystallization, which
38 may occur in the use of thermal methods such as
39 cocrystallization from the melt.19 A drawback of solution
40 growth, however, is the high risk of precipitating the pure
41 components because of their potentially significant solubility
42 differences,20 or the undesired formation of solvates.21 To avoid
43 this issue, methods that employ less or even no liquid solvent
44 (such as grinding,22 liquid-assisted11 and polymer-assisted
45 grinding,23 and slurrying24) have been devised and applied.
46 We applied the approach of crystallization at solvent
47 interfaces to the cocrystallization of phenazine and mesaconic
48 acid in an earlier study, resulting in the generation of a novel
49 monohydrate cocrystal form.20 Here we report the results of a
50 systematic study that aimed to explore how precipitation at the
51boundary between two immiscible solutions containing the
52coformer molecules, a technique referred to as interfacial
53cocrystallization (IC), is a very effective screening method
54 s1(Scheme 1).
55Recognizing the numerous studies that report the use of
56solvent interfaces to precipitate or crystallize various organic
57and inorganic species,25−29 this study focuses on the
58preparation of pharmaceutical cocrystals at solvent interfaces
59and highlights in particular the large number of experimental
60variations that are possible.
61Using caffeine (caf) and hydroxy-2-naphthoic acids (xH2Ns)
62as model compounds, we show that IC enables fast access to a
63variety of polymorphs, hydrates of pharmaceutical cocrystals, as
64well as cocrystal forms with atypical stoichiometric ratios. We
65further demonstrate how the chemical nature of the solvents,
66solution concentrations, various cocrystallization rates, and the
67surrounding ambient temperatures affect the crystallization
68outcome. We also highlight several key advantages of the IC
69approach, namely, the ability to screen multiple potential
70coformers simultaneously in a single experiment by using
71solutions containing several possible coformers, as well as the
72ability to access a broad variety of crystal forms without the
73knowledge of solubility phase diagrams.
74The studied compounds have previously been investigated in
75the context of crystal engineering and pharmaceutical
76cocrystals;30−34 caf is a widely known central nervous system
77stimulant, while xH2Ns are pharmaceutically active ingredients
78known to exhibit higher activity than salicylate in the treatment
79of stress-mediated diseases.35 The three hydroxy-2-naphthoic
80acids, namely, 1-hydroxy-2-naphthoic acid (1H2N), 3-hydroxy-
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81 2-naphthoic acid (3H2N), and 6-hydroxy-2-naphthoic acid
82 (6H2N), differ significantly in the geometry of their potential
83 hydrogen-bonding interactions (Scheme 1), and therefore in
84 their solubility and cocrystallization performance.
85 The caf:xH2N cocrystals were initially investigated using
86 more traditional solution-based methods by Bucǎr et al.,30 who
87 identified and structurally characterized one cocrystal form for
88 each system, each having a 1:1 stoichiometry (Cambridge
89 Structural Database (CSD) reference codes: KIGKIV,
90 KIGKOB, KIGKUH; henceforth referred to for each case as
91 form I).30 In the study reported here, we pursued the interfacial
92 cocrystallizations of caf with the same three xH2Ns. The
93 reactions involved the layering of two solutions: one being a
94 saturated solution of caffeine in water (a reasonably good
95 solvent for caf), and the second being a nearly saturated
96 solution of xH2N in an organic solvent that is immiscible with
97 water (see SI) and in which the solubility of the acid is high,
98 while the solubility of caf is low (e.g., noncyclic ethers, aliphatic
99 alcohols, and acetic acid esters). Whereas there is no driving
100 force for crystallization to occur because of the low amount of
101 both coformers simultaneously present in either phase, layering
102 the two solutions allows a cocrystal to precipitate at the
103 interface (Scheme 1) owing to its lower free energy. A coformer
104 concentration gradient at the interface then facilitates slow
105 incorporation of coformer molecules from both sides of the
106 interface to the growing cocrystal. In almost every example
107 reported below, crystals suitable for single crystal X-ray studies
108 were obtained.
109 ■ RESULTS AND DISCUSSION
110 1. Effects of Solvent Choice on Cocrystal Composition
111 and Polymorphic Form. 1.1. caf:6H2N Cocrystal. Initial
112 studies focusing on the caf:6H2N system yielded a range of
113 cocrystals of various stoichiometries, as well as new polymorphs
t1 114 and hydrates (Table 1), thus demonstrating the high efficacy of
115 IC in cocrystal screening. Specifically, we were able to
f1 116 reproduce the 1:1 (caf)·(6H2N) cocrystal, initially reported
117 f1by Bucǎr et al. (form I; space group P1̅, Z′ = 1) (Figure 1a), but
118we also obtained an additional new polymorph of this cocrystal,
119namely, form II (see SI document). Form II crystallizes in
120space group P21/c and its structure is based on discrete 2:2
121supramolecular caf:6H2N assemblies, wherein the 6H2N
122molecules form dimers through O−H···O hydrogen bonds
123via an R2
2(8) synthon. The caf molecules are disordered over
124two positions and are bound to the hydroxyl group of 6H2N
125through either an O−H···O hydrogen or an O−H···N
126hydrogen bond via a D(2) synthon (Figure 1b).
127Further IC experiments led to the discovery of a third
128anhydrous cocrystal form, namely, the 2:1 (caf)2·(6H2N)
129cocrystal (see SI). The crystal structure of this material is based
130on discrete three-component caf:6H2N assemblies. In the
131assembly, one caf molecule is bound to 6H2N through an O−
132H···N hydrogen bond via an R2
2(7) synthon, while the second
133caf molecule is disordered over two positions and bound to
134naphthoic acid through an O−H···N or O−H···O hydrogen
135bond (depending on the caf orientation) via a D(2) synthon
136(Figure 1d).
137Notably, two hydrated caf:6H2N cocrystal forms were
138discovered: the 1:1:1 (caf)·(6H2N)·(H2O) and the 2:3:1
139(caf)2·(6H2N)3·(H2O) cocrystal monohydrate.
36 The crystal
140structure of the (caf)·(6H2N)·(H2O) cocrystal monohydrate is
141based on two-dimensional flat hydrogen-bonded layers. Within
142the layers, caf and disordered 6H2N molecules are connected
143by O−H···N hydrogen bonds via R22(7) synthons. The
144caf:6H2N molecular pairs are further linked through water
145molecules by O−H···O hydrogen bonds through D(2)
146synthons (Figure 1e). Structural analyses of the (caf)2·
147(6H2N)3·(H2O) monohydrate revealed that its structure is
148based on interpenetrated three-dimensional caf:6H2N:H2O
149assemblies. In these structures, caf and 6H2N are linked into
150molecular chains that are sustained by O−H···N and O−H···O
151hydrogen bonds via R2
2(7) and D(2) synthons. The one-
152dimensional structure is extended into three dimensions by a
153disordered pair of 6H2N:H2O molecules (Figure 1f).
154It should be noted that it was not possible to obtain
155reproducibly phase-pure samples of the previously reported
156anhydrous 1:1 cocrystal (form I) using nearly saturated
157solutions of the coformers. This form was initially only
158observed 3 days after harvesting all (caf)·(6H2N)·(H2O)
159crystals at the solvent interface, when a second crop of large
160single crystals of form I emerged.
161The mechanisms leading to the formation of the large variety
162of caf:6H2N cocrystal forms are not understood at this time.37
Scheme 1. Representation of an Interfacial Cocrystallization
Experiment Whereby Two Saturated Solutions of Coformers
in Immiscible Solvents Are Prepared Separately and Then
Combined (Providing an Interface at Which
Cocrystallization Can Occur) (Top); and Molecular
Structures of caf, 1H2N, 3H2N, and 6H2N (Bottom)
Table 1. Solvents Used in Combination with Water to
Crystallize Various caf:xH2N Cocrystal Forms
xH2N organic solvent cocrystal form obtained
6H2N ButOAC 1:1, form I
EtOAc 1:1, form II
DIPEa 1:1, form III
DIPE/xylenea 1:1, form IV
ButOAC 1:1, monohydrate
DIPE 2:1
2-butanonea 2:3, monohydrate
1H2N EtOAC 1:1, form I
DIPE 1:1, form II
3H2N EtOAC 1:1, form I
DIPE 1:1, form II
aSupersaturated solution.
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163 We do, however, speculate that access to the crystal form with a
164 different atypical stoichiometry may be attributed to solubility
165 effects. In particular, we believe that a change from a 2:1 to 1:1
166 coformer ratio is likely to be related to the higher solubility of
167 6H2N in butyl acetate compared to diisopropyl ether, leading
168 to a higher concentration of 6H2N at the interface.
169 1.2. caf:1H2N and caf:3H2N Cocrystals. The substantial
170 variety of discovered caf:6H2N cocrystal forms prompted us to
171 extend our studies to the caf:1H2N and caf:3H2N cocrystal
172 systems. A more limited set of experiments soon led not only to
173 the preparation of the previously known cocrystal phases
f2 174 (Figure 2a,b), but also to the discovery of a new polymorph of
175 (caf)·(1H2N) and (caf)·(3H2N), referred to as form II (Table
176 1 and SI). Form II of (caf)·(1H2N) crystallizes in space group
177 P21/n with three caf:1H2N pairs in the asymmetric unit (Z′ =
178 3). Each of the pairs is held together by O−H···N hydrogen
179 bonds through R2
2(7) synthons, whereby the 1H2N hydroxyl
180 groups are engaged in intramolecular O−H···O hydrogen
181 bonds by a S(6) synthon (Figure 2a). Form II of (caf)·(3H2N)
182 crystallizes in space group P21/n with one molecule of caf and
183 3H2N in the asymmetric unit (Z′ = 1). The cocrystal
184 components are also held together by O−H···N and O−H···
185 O hydrogen bonds through R2
2(7) and S(6) synthons (Figure
186 2b).
187 It was also established that, in the cases of the caf:1H2N and
188 caf:3H2N cocrystal systems, a change in polymorphic form of
189 the product was achieved by varying the interface conditions, as
190 shown in Table 1.
191 Specifically, the use of more polar solvents favored in both
192 cases the crystallization of form I. That solvent properties can
193 influence the polymorphic outcome of IC processes is not
194 unexpected,9 as it mirrors what has been widely reported for
195 conventional solution crystallizations. With specific regard to
196 cocrystal polymorphism, however, it should be noted that
197 problems associated with the precipitation of individual
198 coformers during conventional solution crystallization experi-
199 ments20 are minimized.
2002. Effects of Solution Concentrations on Polymorphic
201Outcome for the caf:6H2N Cocrystal. In an attempt to
202facilitate the growth of single crystals during the IC
203experiments, we resorted to the layering of supersaturated
204solutions of the cocrystal components. Such an approach has
205not only led to the formation of crystals suitable for single
206crystal X-ray diffraction studies, but also enabled, to our
Figure 1. Supramolecular caf:6H2N assemblies in the crystal structures of (a) anhydrous (caf)·(6H2N), form I; (b) anhydrous (caf)·(6H2N), form
II; (c) anhydrous (caf)·(6H2N), form III; (d) anhydrous (caf)2·(6H2N); (e) (caf)·(6H2N)·(H2O) monohydrate; (f) (caf)2·(6H2N)3·(H2O)
monohydrate. Minor occupation sites (up to 50%) of disordered molecules are shown using the “wireframe” display style. Hydrogen atoms are
omitted to enhance clarity.
Figure 2. (a) Crystallographically independent caf:1H2N assemblies
in the (caf)·(1H2N) cocrystal forms I and II. (b) Supramolecular
caf:3H2N assembly found in the crystal structures of (caf)·(3H2N)
forms I and II (highlighted in the rounded rectangle) and crystal
packing diagrams of (caf)·(3H2N) forms I and II. Hydrogen atoms
are omitted to enhance clarity.
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207 surprise, the appearance of new polymorphs. In particular, two
208 new polymorphs of the caf:6H2N cocrystal were discovered,
209 namely, forms III and IV (see SI). These two forms, however,
210 appeared only occasionally and single crystals suitable for
211 structural analyses could be produced only in the case of form
212 III.38
213 Crystallographic analyses revealed that form III crystallizes in
214 space group P21/c with three molecules of both caf and 6H2N
215 in the asymmetric unit (Z′ = 3). The crystal structure is based
216 on two crystallographically independent types of 2:2 caf:6H2N
217 assemblies similar to those seen in forms I and II. One is
218 centrosymmetric with disordered 6H2N and ordered caf
219 molecules that are held together by O−H···O hydrogen
220 bonds through R2
2(8) and D(2) synthons. The second
221 assembly is noncentrosymmetric and also based on disordered
222 caf and ordered 6H2N molecules, which are sustained by the
223 same types of hydrogen bonds and synthons as those in the first
224 assembly type (Figure 1c).
225 It was also observed that the use of supersaturated solutions
226 of caf and 6H2N (using polar solvents) regularely leads to the
227 crystallization of form I of the caf:6H2N cocrystal, which could
228 not be reliably achieved with the use of nearly saturated
229 solutions (see Table 1 and SI).
230 3. Effects of Temperature on Cocrystallization
231 Kinetics and Polymorphic form. Saturated solutions of caf
232 in water and of the three xH2Ns in DIPE were prepared,
233 layered, and left for crystallization at a range of different
234 temperatures to monitor the influence of the crystallization rate
235 on the outcome of interfacial cocrystallization. Observations
t2 236 from the resulting IC experiments are summarized in Table 2.
237 In general, the higher the temperature at which interfacial
238 cocrystallization is performed, the faster a cocrystal is formed at
239 the interface. For instance, the precipitation of the (caf)2·
240 (6H2N) cocrystal can be accelerated from 2 days to 4 h by
241 increasing the temperature from 10 to 40 °C. This increase in
242 cocrystallization rate may result from the increased amount of
243 coformer dissolved in solutions at high temperature and/or
244 from increased molecular diffusion rates which facilitate the
245 precipitation process. Accompanying the faster cocrystallization
246 and nucleation processes at higher temperature was a reduction
247 in the particle size of the resulting crystals (see SI Figure S2).
248 Low-temperature interfacial crystallizations were, therefore,
249 found to be most appropriate for the growth of large single
250 crystals suitable for structure determination.
251 Temperature was also observed to have an influence on the
252 polymorphic outcome (Table 2). With the caf:1H2N system,
253 on increasing the crystallization temperature to 40 °C, a
254 mixture of forms I and II was obtained (rather than pure form
255 II, as seen at lower temperatures). We suggest that form II is
256 still the form which precipitates at the interface, and the
257 increased temperature merely increases the rate of conversion
258 to the more stable form I.39 This is certainly the case for the
259caf:3H2N system where form II precipitates at the interface
260shortly after layering of the two solutions, but at higher
261temperature undergoes conversion to form I within hours.
2624. Effects of Stirring. The effect of high-speed stirring (at
263750 rpm) during interfacial cocrystallization was investigated
264for the three caf:xH2N cocrystals using magnetic stir bars (see
265 t3Table 3). This agitation resulted in the formation of an
266emulsion of the two immiscible solutions wherein small
267droplets were created and the curvature of the liquid−liquid
268interface increased. The crystallization rate of each of the
269cocrystals increased dramatically as a result. Stirring also led to
270a change in the polymorphic form which was obtained for the
271caf:3H2N cocrystal, with form I rather than form II being
272isolated, and a change in the stoichiometry of the caf:6H2N
273cocrystal form 1:1 to 2:1. The origins of these polymorphic and
274stoichiometric variations, which could be based on the
275increased curvature of the interface, or due to the shear
276introduced to the system by stirring, is still under investigation.
2775. Competitive Coformer Studies. The potential
278application of IC to screening for cocrystal formation between
279a compound of interest and multiple putative coformer
280molecules in a simultaneous manner was investigated by
281layering a saturated aqueous solution of caffeine and a solution
282of DIPE saturated with both 1H2N and phenazine. Phenazine,
283in contrast to 1H2N, does not possess a carboxylic acid group
284and was, therefore, not expected to form a cocrystal with
285caffeine. After combining the two solutions, the known
286caf:1H2N cocrystal precipitated at the interface. Phenazine
287did not crystallize either as a pure phase or as a cocrystal with
288caffeine, thus demonstrating that cocrystallization of caf with a
289coformer at a solvent interface is not inhibited by the presence
290of a molecule which does not form a cocrystal.
291To investigate a situation where competition between
292coformer molecules is possible during interfacial cocrystalliza-
293tion a saturated solution of caffeine in water was combined with
294a solution of DIPE saturated with both 1H2N and 3H2N (the
295overall molar ratio of caf:1H2N:3H2N was approximately
2961:3:3). PXRD indicated that the resulting precipitate at the
297solvent interface contained a mixture of (caf)·(1H2N) form II
298and (caf)·(3H2N) form II (see Figure S1 in SI).
299■ SUMMARY AND OUTLOOK
300It has been demonstrated that IC is a tunable and efficient
301technique to produce a range of multicomponent crystal forms.
302For the three caf:xH2N cocrystals investigated in this study, IC
303yielded at least one new cocrystal form for each system.
304Furthermore, with appropriate control of temperature, solution
305concentrations, solvent selection, and the cocrystallization rate,
306it was possible to grow single crystals at the interface for all
307three systems.
308Interfacial cocrystallization can be applied to screen quickly
309and simultaneously for cocrystal formation between a drug
310molecule and several potential coformer molecules in one
311crystallization vessel. We have also demonstrated that a
Table 2. Effects of Temperature on Cocrystal Formation
xH2N 10 °C 20 °C 40 °C
1H2N 1:1, form II 1:1, form II 1:1, form I + II
10 min 5 min <1 min
3H2N 1:1, form II 1:1, form II 1:1, form II
15 min 8 min 1 min
6H2N 2:1 2:1 2:1
2 days 1 day 4 h
Table 3. Effects of Stirring at Room Temperature on
Cocrystal Formation
xH2N solvent static conditions stirred solutions
1H2N DIPE 1:1, form II 1:1, form II
3H2N DIPE 1:1, form II 1:1, form I
6H2N DIPE 2:1 1:1, form I
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312 cocrystal will readily form at the interface of two immiscible
313 solvents, despite the direct interactions and competition of
314 coformers within the organic solution. The great variety of
315 identified caf:xH2N cocrystal forms obtained, as well as its
316 convenience, establishes the merit of this crystallization method
317 in the context of cocrystal screening and materials discovery.
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